Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-08 |
2024-03 |
-1.17 |
-1 |
0.17 |
14.53% |
2024-03-07 |
2023-12 |
-1.69 |
-0.32 |
1.37 |
81.07% |
2023-11-14 |
2023-09 |
-1.79 |
-0.61 |
1.18 |
65.92% |
2023-08-07 |
2023-06 |
0.09 |
-1.98 |
-2.07 |
-2300.00% |
2023-05-09 |
2023-03 |
2.92 |
0.88 |
-2.04 |
-69.86% |
2023-03-28 |
2022-12 |
-1.86 |
4.33 |
6.19 |
332.80% |
Date |
Firm |
Action |
From |
To |
2023-09-26 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-09-19 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-09-04 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-21 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-08-14 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-07 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-06-02 |
CHIVUKULA PADMANABH |
Chief Operating Officer |
447.45K |
Sale |
2019-08-19 |
FARRELL PETER CRAIG |
Director |
0.00 |
Purchase |
2023-07-13 |
KUMMERFELD KEITH C |
Officer |
950.00 |
Sale |
2022-12-14 |
MARQUET MAGDA |
Director |
0.00 |
Purchase |
2022-11-22 |
PAYNE JOSEPH E |
Chief Executive Officer |
1.48M |
Purchase |
2023-08-14 |
SASSINE ANDY H |
Chief Financial Officer |
270.53K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Federated Hermes, Inc. |
4.78M |
137.05M |
17.97% |
2023-06-29 |
Blackrock Inc. |
1.99M |
57.14M |
7.49% |
2023-06-29 |
State Street Corporation |
1.98M |
56.91M |
7.46% |
2023-09-29 |
ARK Investment Management, LLC |
1.90M |
48.58M |
7.15% |
2023-06-29 |
Vanguard Group Inc |
1.63M |
46.70M |
6.12% |
2023-06-29 |
Nikko Asset Management Americas, Inc. |
1.40M |
40.29M |
5.28% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-07-30 |
Federated Hermes Kaufmann Fund |
2.48M |
86.53M |
9.31% |
2023-07-30 |
Federated Hermes Kaufmann Small Cap Fund |
2.23M |
77.96M |
8.38% |
2023-09-29 |
ARK ETF Tr-ARK Genomic Revolution ETF |
1.89M |
48.17M |
7.09% |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
1.34M |
40.54M |
5.02% |
2023-08-30 |
Fidelity Select Portfolios - Biotechnology |
904.63K |
27.46M |
3.40% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
716.97K |
20.56M |
2.70% |
Dividend |
Date |
0.0085 |
2013-01-08 |
0.0085 |
2013-01-04 |
0.0086 |
2012-12-05 |
0.0086 |
2012-11-06 |
0.0086 |
2012-10-03 |
0.0086 |
2012-09-05 |
Split |
Date |
1 : 7 |
2017-11-16 |